Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Itzhak Nir

Plastic and Reconstructive Surgery Loxahatchee, FL Medical Doctor

NPI 1124015482 CMS profile 231703

13005 Southern Blvd, Ste 232, Loxahatchee, FL 33470

Open in the dashboard

General payments

$18,644

192 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$67,461 paid to institutions, not to them · program years 2019–2022

Through program year 2025, Itzhak Nir of Loxahatchee, FL is reported in the CMS Open Payments database as having received $18,644 across 192 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $67,461 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 89th percentile of Plastic and Reconstructive Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $6,826 37
2024 General $1,901 34
2023 General $690 30
2022 General $433 19
2021 General $245 14
2020 General $203 13
2019 General $8,345 45

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Itzhak Nir
  • Plastic and Reconstructive Surgery median
  • Middle half of Plastic and Reconstructive Surgery
  • National median

In program year 2025, general payments to Itzhak Nir were reported at $6,826. Among 2,070 Plastic and Reconstructive Surgery profiles paid that year, the median was $442 and the middle half received between $150 and $1,242.

Show as a table
Year Itzhak Nir Plastic and Reconstructive Surgery median Middle half National median
2019 $8,345 $335 $121–$1,264 $163
2020 $203 $162 $57–$417 $114
2021 $245 $245 $89–$735 $132
2022 $433 $325 $120–$932 $149
2023 $690 $343 $129–$999 $160
2024 $1,901 $390 $141–$1,085 $164
2025 $6,826 $442 $150–$1,242 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Allergan Inc. $8,425 46 payments
  2. Davol Inc. $5,915 2 payments
  3. TELA Bio, Inc. $1,878 67 payments
  4. Integra LifeSciences Corporation $892 14 payments
  5. Mentor Worldwide LLC $680 27 payments
  6. TEI Biosciences Inc $227 17 payments
  7. Revance Therapeutics, Inc. $220 3 payments
  8. Ethicon US, LLC $122 1 payment
  9. Sientra, Inc. $111 6 payments
  10. AbbVie, Inc. $63 3 payments
  11. Other $111 6 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Gift $7,454 3 payments
  2. Honoraria $5,850 1 payment
  3. Food and Beverage $4,689 186 payments
  4. Long term medical supply or device loan $652 2 payments
Products named General payments · program years 2019–2025
  1. NATRELLE $8,090 21 payments
  2. OviTex Reinforced Bioscaffold With Permanent Polymer (OviTex) $1,111 48 payments
  3. OviTex 2S $767 19 payments
  4. DuraSorb Monofilament Mesh $652 2 payments
  5. ARTOURA Breast Tissue Expander $603 22 payments
  6. MENTOR MemoryGel Resterilizable Gel Sizer $600 24 payments
  7. SURGIMEND Recon-Skin And Wound $306 22 payments
  8. DAXXIFY $220 3 payments
  9. NATRELLE SALINE-FILLED BREAST IMPLANTS $163 9 payments
  10. SURGIMEND Recon-Skin And Wound $162 7 payments
  11. Other $1,351 52 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 6 drugs

Part D claims

108

Median for Plastic and Reconstructive Surgery: 61

Drug cost

$706

Median for Plastic and Reconstructive Surgery: $369

Branded share of claims

17.6%

Median for Plastic and Reconstructive Surgery: 30%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Minoxidil Generic 25 $269
Cephalexin Generic 25 $159
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 19 $146
Methylprednisolone Generic 14 $92
Diazepam Generic 14 $23
Ondansetron Hcl Generic 11 $17

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 2,638 Part D prescribers listed as Plastic and Reconstructive Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 13 billing codes

Paid by Medicare

$5,097

Medicare's payments for the services billed

Medicare patients

14

Average age 72

Services billed

27

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Heart failure 0%
COPD 0%
Depression 0%
Alzheimer's or dementia 0%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

2 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
DAXXIFY
  • REVANCE THERAPEUTICS, INC. $44
$44 — —
Exparel
  • Pacira Pharmaceuticals Incorporated $15
$15 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

192 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Plastic and Reconstructive Surgery in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record